A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2018
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Pegaspargase; Pegaspargase; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Sep 2018 Status changed from active, no longer recruiting to completed.
- 21 Jan 2018 Status changed from discontinued to active, no longer recruiting.
- 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.